Publications Anita Langerød

Publications by Anita Langerød

54 publications found

Publications 2024

1. Ohnstad HO, Blix ES, Akslen LA, Gilje B, Raj SX, Skjerven H, Borgen E, Janssen EAM, Mortensen E, Brekke MB, Falk RS, Schlichting E, Boge B, Songe-Møller S, Olsson P, Heie A, Mannsåker B, Vestlid MA, Kursetgjerde T, Gravdehaug B, Suhrke P, Sanchez E, Bublevic J, Røe OD, Geitvik GA et al. (2024)
   Impact of Prosigna test on adjuvant treatment decision in lymph node-negative early breast cancer-a prospective national multicentre study (EMIT-1)
   ESMO Open, 9 (6), 103475
   DOI 10.1016/j.esmoop.2024.103475, PubMed 38838499

Publications 2023

1. Nguyen HL, Geukens T, Maetens M, Aparicio S, Bassez A, Borg A, Brock J, Broeks A, Caldas C, Cardoso F, De Schepper M, Delorenzi M, Drukker CA, Glas AM, Green AR, Isnaldi E, Eyfjörð J, Khout H, Knappskog S, Krishnamurthy S, Lakhani SR, Langerod A, Martens JWM, McCart Reed AE, Murphy L et al. (2023)
   Obesity-associated changes in molecular biology of primary breast cancer
   Nat Commun, 14 (1), 4418
   DOI 10.1038/s41467-023-39996-z, PubMed 37479706

Publications 2022

1. Castro-Mondragon JA, Aure MR, Lingjærde OC, Langerød A, Martens JWM, Børresen-Dale AL, Kristensen VN, Mathelier A (2022)
   Cis-regulatory mutations associate with transcriptional and post-transcriptional deregulation of gene regulatory programs in cancers
   Nucleic Acids Res, 50 (21), 12131-12148
   DOI 10.1093/nar/gkac1143, PubMed 36477895

Publications 2020

1. Pladsen AV, Nilsen G, Rueda OM, Aure MR, Borgan Ø, Liestøl K, Vitelli V, Frigessi A, Langerød A, Mathelier A, OSBREAC, Engebråten O, Kristensen V, Wedge DC, Van Loo P, Caldas C, Børresen-Dale AL, Russnes HG, Lingjærde OC (2020)
   DNA copy number motifs are strong and independent predictors of survival in breast cancer
   Commun Biol, 3 (1), 153
   DOI 10.1038/s42003-020-0884-6, PubMed 32242091

Publications 2019

1. Nik-Zainal S, Davies H, Staaf J, Ramakrishna M, Glodzik D, Zou X, Martincorena I, Alexandrov LB, Martin S, Wedge DC, Van Loo P, Ju YS, Smid M, Brinkman AB, Morganella S, Aure MR, Lingjærde OC, Langerød A, Ringnér M, Ahn SM, Boyault S, Brock JE, Broeks A, Butler A, Desmedt C et al. (2019)
   Author Correction: Landscape of somatic mutations in 560 breast cancer whole-genome sequences
   Nature, 566 (7742), E1
   DOI 10.1038/s41586-019-0883-2, PubMed 30659290

Publications 2017

1. Leroy B, Ballinger ML, Baran-Marszak F, Bond GL, Braithwaite A, Concin N, Donehower LA, El-Deiry WS, Fenaux P, Gaidano G, Langerød A, Hellstrom-Lindberg E, Iggo R, Lehmann-Che J, Mai PL, Malkin D, Moll UM, Myers JN, Nichols KE, Pospisilova S, Ashton-Prolla P, Rossi D, Savage SA, Strong LC, Tonin PN et al. (2017)
   Recommended Guidelines for Validation, Quality Control, and Reporting of TP53 Variants in Clinical Practice
   Cancer Res, 77 (6), 1250-1260
   DOI 10.1158/0008-5472.CAN-16-2179, PubMed 28254861
2. Samuel N, Id Said B, Guha T, Novokmet A, Li W, Silwal-Pandit L, Børrsen-Dale AL, Langerød A, Hudson TJ, Malkin D (2017)
   Assessment of TP53 Polymorphisms and MDM2 SNP309 in Premenopausal Breast Cancer Risk
   Hum Mutat, 38 (3), 265-268
   DOI 10.1002/humu.23154, PubMed 27957778
3. Silwal-Pandit L, Langerød A, Børresen-Dale AL (2017)
   TP53 Mutations in Breast and Ovarian Cancer
   Cold Spring Harb Perspect Med, 7 (1)
   DOI 10.1101/cshperspect.a026252, PubMed 27815305
4. Silwal-Pandit L, Nord S, von der Lippe Gythfeldt H, Møller EK, Fleischer T, Rødland E, Krohn M, Borgen E, Garred Ø, Olsen T, Vu P, Skjerven H, Fangberget A, Holmen MM, Schlitchting E, Wille E, Nordberg Stokke M, Moen Vollan HK, Kristensen V, Langerød A, Lundgren S, Wist E, Naume B, Lingjærde OC, Børresen-Dale AL et al. (2017)
   The Longitudinal Transcriptional Response to Neoadjuvant Chemotherapy with and without Bevacizumab in Breast Cancer
   Clin Cancer Res, 23 (16), 4662-4670
   DOI 10.1158/1078-0432.CCR-17-0160, PubMed 28487444

Publications 2016

1. Nik-Zainal S, Davies H, Staaf J, Ramakrishna M, Glodzik D, Zou X, Martincorena I, Alexandrov LB, Martin S, Wedge DC, Van Loo P, Ju YS, Smid M, Brinkman AB, Morganella S, Aure MR, Lingjærde OC, Langerød A, Ringnér M, Ahn SM, Boyault S, Brock JE, Broeks A, Butler A, Desmedt C et al. (2016)
   Landscape of somatic mutations in 560 breast cancer whole-genome sequences
   Nature, 534 (7605), 47-54
   DOI 10.1038/nature17676, PubMed 27135926
2. Shlien A, Raine K, Fuligni F, Arnold R, Nik-Zainal S, Dronov S, Mamanova L, Rosic A, Ju YS, Cooke SL, Ramakrishna M, Papaemmanuil E, Davies HR, Tarpey PS, Van Loo P, Wedge DC, Jones DR, Martin S, Marshall J, Anderson E, Hardy C, ICGC Breast Cancer Working Group, Oslo Breast Cancer Research Consortium, Barbashina V, Aparicio SA, Sauer T et al. (2016)
   Direct Transcriptional Consequences of Somatic Mutation in Breast Cancer
   Cell Rep, 16 (7), 2032-46
   DOI 10.1016/j.celrep.2016.07.028, PubMed 27498871
3. Smid M, Rodríguez-González FG, Sieuwerts AM, Salgado R, Prager-Van der Smissen WJ, Vlugt-Daane MV, van Galen A, Nik-Zainal S, Staaf J, Brinkman AB, van de Vijver MJ, Richardson AL, Fatima A, Berentsen K, Butler A, Martin S, Davies HR, Debets R, Gelder ME, van Deurzen CH, MacGrogan G, Van den Eynden GG, Purdie C, Thompson AM, Caldas C et al. (2016)
   Breast cancer genome and transcriptome integration implicates specific mutational signatures with immune cell infiltration
   Nat Commun, 7, 12910
   DOI 10.1038/ncomms12910, PubMed 27666519

Publications 2015

1. Silwal-Pandit L, Russnes H, Borgen E, Skarpeteig V, Moen Vollan HK, Schlichting E, Kåresen R, Naume B, Børresen-Dale AL, Farnebo M, Langerød A (2015)
   The Sub-Cellular Localization of WRAP53 Has Prognostic Impact in Breast Cancer
   PLoS One, 10 (10), e0139965
   DOI 10.1371/journal.pone.0139965, PubMed 26460974

Publications 2014

1. Quigley D, Silwal-Pandit L, Dannenfelser R, Langerød A, Vollan HK, Vaske C, Siegel JU, Troyanskaya O, Chin SF, Caldas C, Balmain A, Børresen-Dale AL, Kristensen V (2014)
   Lymphocyte Invasion in IC10/Basal-Like Breast Tumors Is Associated with Wild-Type TP53
   Mol Cancer Res, 13 (3), 493-501
   DOI 10.1158/1541-7786.MCR-14-0387, PubMed 25351767
2. Silwal-Pandit L, Vollan HK, Chin SF, Rueda OM, McKinney S, Osako T, Quigley DA, Kristensen VN, Aparicio S, Børresen-Dale AL, Caldas C, Langerød A (2014)
   TP53 mutation spectrum in breast cancer is subtype specific and has distinct prognostic relevance
   Clin Cancer Res, 20 (13), 3569-80
   DOI 10.1158/1078-0432.CCR-13-2943, PubMed 24803582

Publications 2013

1. Kalous O, Conklin D, Desai AJ, Dering J, Goldstein J, Ginther C, Anderson L, Lu M, Kolarova T, Eckardt MA, Langerød A, Børresen-Dale AL, Slamon DJ, Finn RS (2013)
   AMG 900, pan-Aurora kinase inhibitor, preferentially inhibits the proliferation of breast cancer cell lines with dysfunctional p53
   Breast Cancer Res Treat, 141 (3), 397-408
   DOI 10.1007/s10549-013-2702-z, PubMed 24091768

Publications 2012

1. Curtis C, Shah SP, Chin SF, Turashvili G, Rueda OM, Dunning MJ, Speed D, Lynch AG, Samarajiwa S, Yuan Y, Gräf S, Ha G, Haffari G, Bashashati A, Russell R, McKinney S, METABRIC Group, Langerød A, Green A, Provenzano E, Wishart G, Pinder S, Watson P, Markowetz F, Murphy L et al. (2012)
   The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups
   Nature, 486 (7403), 346-52
   DOI 10.1038/nature10983, PubMed 22522925
2. Freed-Pastor WA, Mizuno H, Zhao X, Langerød A, Moon SH, Rodriguez-Barrueco R, Barsotti A, Chicas A, Li W, Polotskaia A, Bissell MJ, Osborne TF, Tian B, Lowe SW, Silva JM, Børresen-Dale AL, Levine AJ, Bargonetti J, Prives C (2012)
   Mutant p53 disrupts mammary tissue architecture via the mevalonate pathway
   Cell, 148 (1-2), 244-58
   DOI 10.1016/j.cell.2011.12.017, PubMed 22265415
3. Natrajan R, Mackay A, Wilkerson PM, Lambros MB, Wetterskog D, Arnedos M, Shiu KK, Geyer FC, Langerød A, Kreike B, Reyal F, Horlings HM, van de Vijver MJ, Palacios J, Weigelt B, Reis-Filho JS (2012)
   Functional characterization of the 19q12 amplicon in grade III breast cancers
   Breast Cancer Res, 14 (2), R53
   DOI 10.1186/bcr3154, PubMed 22433433
4. Nik-Zainal S, Alexandrov LB, Wedge DC, Van Loo P, Greenman CD, Raine K, Jones D, Hinton J, Marshall J, Stebbings LA, Menzies A, Martin S, Leung K, Chen L, Leroy C, Ramakrishna M, Rance R, Lau KW, Mudie LJ, Varela I, McBride DJ, Bignell GR, Cooke SL, Shlien A, Gamble J et al. (2012)
   Mutational processes molding the genomes of 21 breast cancers
   Cell, 149 (5), 979-93
   DOI 10.1016/j.cell.2012.04.024, PubMed 22608084
5. Nik-Zainal S, Van Loo P, Wedge DC, Alexandrov LB, Greenman CD, Lau KW, Raine K, Jones D, Marshall J, Ramakrishna M, Shlien A, Cooke SL, Hinton J, Menzies A, Stebbings LA, Leroy C, Jia M, Rance R, Mudie LJ, Gamble SJ, Stephens PJ, McLaren S, Tarpey PS, Papaemmanuil E, Davies HR et al. (2012)
   The life history of 21 breast cancers
   Cell, 149 (5), 994-1007
   DOI 10.1016/j.cell.2012.04.023, PubMed 22608083
6. Stavnes HT, Nymoen DA, Langerød A, Holth A, Børresen Dale AL, Davidson B (2012)
   AZGP1 and SPDEF mRNA expression differentiates breast carcinoma from ovarian serous carcinoma
   Virchows Arch, 462 (2), 163-73
   DOI 10.1007/s00428-012-1347-3, PubMed 23242172
7. Stephens PJ, Tarpey PS, Davies H, Van Loo P, Greenman C, Wedge DC, Nik-Zainal S, Martin S, Varela I, Bignell GR, Yates LR, Papaemmanuil E, Beare D, Butler A, Cheverton A, Gamble J, Hinton J, Jia M, Jayakumar A, Jones D, Latimer C, Lau KW, McLaren S, McBride DJ, Menzies A et al. (2012)
   The landscape of cancer genes and mutational processes in breast cancer
   Nature, 486 (7403), 400-4
   DOI 10.1038/nature11017, PubMed 22722201

Publications 2011

1. Hung T, Wang Y, Lin MF, Koegel AK, Kotake Y, Grant GD, Horlings HM, Shah N, Umbricht C, Wang P, Wang Y, Kong B, Langerød A, Børresen-Dale AL, Kim SK, van de Vijver M, Sukumar S, Whitfield ML, Kellis M, Xiong Y, Wong DJ, Chang HY (2011)
   Extensive and coordinated transcription of noncoding RNAs within cell-cycle promoters
   Nat Genet, 43 (7), 621-9
   DOI 10.1038/ng.848, PubMed 21642992
2. van den Broek AJ, Broeks A, Horlings HM, Canisius SV, Braaf LM, Langerød A, Van't Veer LJ, Schmidt MK (2011)
   Association of the germline TP53 R72P and MDM2 SNP309 variants with breast cancer survival in specific breast tumor subgroups
   Breast Cancer Res Treat, 130 (2), 599-608
   DOI 10.1007/s10549-011-1615-y, PubMed 21667122
3. Zhao X, Rødland EA, Sørlie T, Naume B, Langerød A, Frigessi A, Kristensen VN, Børresen-Dale AL, Lingjærde OC (2011)
   Combining gene signatures improves prediction of breast cancer survival
   PLoS One, 6 (3), e17845
   DOI 10.1371/journal.pone.0017845, PubMed 21423775

Publications 2010

1. Anaganti S, Fernández-Cuesta L, Langerød A, Hainaut P, Olivier M (2010)
   p53-Dependent repression of focal adhesion kinase in response to estradiol in breast cancer cell-lines
   Cancer Lett, 300 (2), 215-24
   DOI 10.1016/j.canlet.2010.10.008, PubMed 21071137
2. de Neergaard M, Kim J, Villadsen R, Fridriksdottir AJ, Rank F, Timmermans-Wielenga V, Langerød A, Børresen-Dale AL, Petersen OW, Rønnov-Jessen L (2010)
   Epithelial-stromal interaction 1 (EPSTI1) substitutes for peritumoral fibroblasts in the tumor microenvironment
   Am J Pathol, 176 (3), 1229-40
   DOI 10.2353/ajpath.2010.090648, PubMed 20133812
3. Holstege H, Horlings HM, Velds A, Langerød A, Børresen-Dale AL, van de Vijver MJ, Nederlof PM, Jonkers J (2010)
   BRCA1-mutated and basal-like breast cancers have similar aCGH profiles and a high incidence of protein truncating TP53 mutations
   BMC Cancer, 10, 654
   DOI 10.1186/1471-2407-10-654, PubMed 21118481
4. Russnes HG, Vollan HKM, Lingjærde OC, Krasnitz A, Lundin P, Naume B, Sørlie T, Borgen E, Rye IH, Langerød A, Chin SF, Teschendorff AE, Stephens PJ, Månér S, Schlichting E, Baumbusch LO, Kåresen R, Stratton MP, Wigler M, Caldas C, Zetterberg A, Hicks J, Børresen-Dale AL (2010)
   Genomic architecture characterizes tumor progression paths and fate in breast cancer patients
   Sci Transl Med, 2 (38), 38ra47
   DOI 10.1126/scitranslmed.3000611, PubMed 20592421

Publications 2009

1. Bocanegra M, Bergamaschi A, Kim YH, Miller MA, Rajput AB, Kao J, Langerød A, Han W, Noh DY, Jeffrey SS, Huntsman DG, Børresen-Dale AL, Pollack JR (2009)
   Focal amplification and oncogene dependency of GAB2 in breast cancer
   Oncogene, 29 (5), 774-9
   DOI 10.1038/onc.2009.364, PubMed 19881546
2. Olivier M, Petitjean A, Teague J, Forbes S, Dunnick JK, den Dunnen JT, Langerød A, Wilkinson JM, Vihinen M, Cotton RG, Hainaut P, IARC, EC FP6 (2009)
   Somatic mutation databases as tools for molecular epidemiology and molecular pathology of cancer: proposed guidelines for improving data collection, distribution, and integration
   Hum Mutat, 30 (3), 275-82
   DOI 10.1002/humu.20832, PubMed 19006239
3. Stephens PJ, McBride DJ, Lin ML, Varela I, Pleasance ED, Simpson JT, Stebbings LA, Leroy C, Edkins S, Mudie LJ, Greenman CD, Jia M, Latimer C, Teague JW, Lau KW, Burton J, Quail MA, Swerdlow H, Churcher C, Natrajan R, Sieuwerts AM, Martens JW, Silver DP, Langerød A, Russnes HE et al. (2009)
   Complex landscapes of somatic rearrangement in human breast cancer genomes
   Nature, 462 (7276), 1005-10
   DOI 10.1038/nature08645, PubMed 20033038
4. Zhou W, Muggerud AA, Vu P, Due EU, Sørlie T, Børresen-Dale AL, Wärnberg F, Langerød A (2009)
   Full sequencing of TP53 identifies identical mutations within in situ and invasive components in breast cancer suggesting clonal evolution
   Mol Oncol, 3 (3), 214-9
   DOI 10.1016/j.molonc.2009.03.001, PubMed 19403344

Publications 2008

1. Bergamaschi A, Kim YH, Kwei KA, La Choi Y, Bocanegra M, Langerød A, Han W, Noh DY, Huntsman DG, Jeffrey SS, Børresen-Dale AL, Pollack JR (2008)
   CAMK1D amplification implicated in epithelial-mesenchymal transition in basal-like breast cancer
   Mol Oncol, 2 (4), 327-39
   DOI 10.1016/j.molonc.2008.09.004, PubMed 19383354
2. Holm R, Kraus I, Skomedal H, Langerød A, Kristensen GB, Lyng H (2008)
   Human papillomavirus DNA and e6/e7 mRNA status in relation to survival of patients treated for cervical squamous cell carcinoma
   Open Virol J, 2, 74-81
   DOI 10.2174/1874357900802010074, PubMed 19440467
3. Pietersen AM, Horlings HM, Hauptmann M, Langerød A, Ajouaou A, Cornelissen-Steijger P, Wessels LF, Jonkers J, van de Vijver MJ, van Lohuizen M (2008)
   EZH2 and BMI1 inversely correlate with prognosis and TP53 mutation in breast cancer
   Breast Cancer Res, 10 (6), R109
   DOI 10.1186/bcr2214, PubMed 19099573

Publications 2007

1. Chanock SJ, Burdett L, Yeager M, Llaca V, Langerød A, Presswalla S, Kaaresen R, Strausberg RL, Gerhard DS, Kristensen V, Perou CM, Børresen-Dale AL (2007)
   Somatic sequence alterations in twenty-one genes selected by expression profile analysis of breast carcinomas
   Breast Cancer Res, 9 (1), R5
   DOI 10.1186/bcr1637, PubMed 17224074
2. Garcia-Closas M, Kristensen V, Langerød A, Qi Y, Yeager M, Burdett L, Welch R, Lissowska J, Peplonska B, Brinton L, Gerhard DS, Gram IT, Perou CM, Børresen-Dale AL, Chanock S (2007)
   Common genetic variation in TP53 and its flanking genes, WDR79 and ATP1B2, and susceptibility to breast cancer
   Int J Cancer, 121 (11), 2532-8
   DOI 10.1002/ijc.22985, PubMed 17683073
3. Garcia-Closas M, Troester MA, Qi Y, Langerød A, Yeager M, Lissowska J, Brinton L, Welch R, Peplonska B, Gerhard DS, Gram IT, Kristensen V, Børresen-Dale AL, Chanock S, Perou CM (2007)
   Common genetic variation in GATA-binding protein 3 and differential susceptibility to breast cancer by estrogen receptor alpha tumor status
   Cancer Epidemiol Biomarkers Prev, 16 (11), 2269-75
   DOI 10.1158/1055-9965.EPI-07-0449, PubMed 18006915
4. Kapp AV, Jeffrey SS, Langerod A, Borresen-Dale AL, Han W, Noh DY, Bukholm IRK, Nicolau M, Brown PO, Tibshirani R (2007)
   Discovery and validation of breast cancer subtypes (vol 8, pg 101, 2007)
   BMC Genomics, 8, 101
   DOI 10.1186/1471-2164-8-101
5. Langerød A, Zhao H, Borgan Ø, Nesland JM, Bukholm IR, Ikdahl T, Kåresen R, Børresen-Dale AL, Jeffrey SS (2007)
   TP53 mutation status and gene expression profiles are powerful prognostic markers of breast cancer
   Breast Cancer Res, 9 (3), R30
   DOI 10.1186/bcr1675, PubMed 17504517

Publications 2006

1. Baumbusch LO, Myhre S, Langerød A, Bergamaschi A, Geisler SB, Lønning PE, Deppert W, Dornreiter I, Børresen-Dale AL (2006)
   Expression of full-length p53 and its isoform Deltap53 in breast carcinomas in relation to mutation status and clinical parameters
   Mol Cancer, 5, 47
   DOI 10.1186/1476-4598-5-47, PubMed 17054774
2. Kapp AV, Jeffrey SS, Langerød A, Børresen-Dale AL, Han W, Noh DY, Bukholm IR, Nicolau M, Brown PO, Tibshirani R (2006)
   Discovery and validation of breast cancer subtypes
   BMC Genomics, 7, 231
   DOI 10.1186/1471-2164-7-231, PubMed 16965636
3. Olivier M, Langerød A, Carrieri P, Bergh J, Klaar S, Eyfjord J, Theillet C, Rodriguez C, Lidereau R, Bièche I, Varley J, Bignon Y, Uhrhammer N, Winqvist R, Jukkola-Vuorinen A, Niederacher D, Kato S, Ishioka C, Hainaut P, Børresen-Dale AL (2006)
   The clinical value of somatic TP53 gene mutations in 1,794 patients with breast cancer
   Clin Cancer Res, 12 (4), 1157-67
   DOI 10.1158/1078-0432.CCR-05-1029, PubMed 16489069

Publications 2005

1. Kristensen VN, Sørlie T, Geisler J, Langerød A, Yoshimura N, Kåresen R, Harada N, Lønning PE, Børresen-Dale AL (2005)
   Gene expression profiling of breast cancer in relation to estrogen receptor status and estrogen-metabolizing enzymes: clinical implications
   Clin Cancer Res, 11 (2 Pt 2), 878s-83s
   PubMed 15701881

Publications 2004

1. Usary J, Llaca V, Karaca G, Presswala S, Karaca M, He X, Langerød A, Kåresen R, Oh DS, Dressler LG, Lønning PE, Strausberg RL, Chanock S, Børresen-Dale AL, Perou CM (2004)
   Mutation of GATA3 in human breast tumors
   Oncogene, 23 (46), 7669-78
   DOI 10.1038/sj.onc.1207966, PubMed 15361840
2. Zhao H, Langerød A, Ji Y, Nowels KW, Nesland JM, Tibshirani R, Bukholm IK, Kåresen R, Botstein D, Børresen-Dale AL, Jeffrey SS (2004)
   Different gene expression patterns in invasive lobular and ductal carcinomas of the breast
   Mol Biol Cell, 15 (6), 2523-36
   DOI 10.1091/mbc.e03-11-0786, PubMed 15034139

Publications 2003

1. Bukholm IR, Husdal A, Nesland JM, Langerød A, Bukholm G (2003)
   Overexpression of cyclin A overrides the effect of p53 alterations in breast cancer patients with long follow-up time
   Breast Cancer Res Treat, 80 (2), 199-206
   DOI 10.1023/A:1024527220362, PubMed 12908823
2. Langerød A, Strømberg M, Chin K, Kristensen VN, Børresen-Dale AL (2003)
   BUB1 infrequently mutated in human breast carcinomas
   Hum Mutat, 22 (5), 420
   DOI 10.1002/humu.9194, PubMed 14517964

Publications 2002

1. Kristiansen M, Langerød A, Knudsen GP, Weber BL, Børresen-Dale AL, Orstavik KH (2002)
   High frequency of skewed X inactivation in young breast cancer patients
   J Med Genet, 39 (1), 30-3
   DOI 10.1136/jmg.39.1.30, PubMed 11826021
2. Langerød A, Bukholm IR, Bregård A, Lønning PE, Andersen TI, Rognum TO, Meling GI, Lothe RA, Børresen-Dale AL (2002)
   The TP53 codon 72 polymorphism may affect the function of TP53 mutations in breast carcinomas but not in colorectal carcinomas
   Cancer Epidemiol Biomarkers Prev, 11 (12), 1684-8
   PubMed 12496062

Publications 1999

1. Arver B, Claro A, Langerød A, Børresen-Dale AL, Lindblom A (1999)
   BRCA1 screening in patients with a family history of breast or ovarian cancer
   Genet Test, 3 (2), 223-6
   DOI 10.1089/gte.1999.3.223, PubMed 10464672

Publications 1998

1. Helland A, Langerød A, Johnsen H, Olsen AO, Skovlund E, Børresen-Dale AL (1998)
   p53 polymorphism and risk of cervical cancer
   Nature, 396 (6711), 530-1; author reply 532
   DOI 10.1038/25034, PubMed 9859987